Real‐world effectiveness of brentuximab vedotin in the treatment of CD30‐positive cutaneous T‐cell lymphoma: A single‐centre retrospective review

2021 ◽  
Author(s):  
M.‐H. Henderson Berg ◽  
K. Davison ◽  
G. Popradi
Keyword(s):  
T Cell ◽  
Real World ◽  
Retrospective Review ◽  
Cell Lymphoma ◽  
Brentuximab Vedotin ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Single Centre

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

The Lancet ◽  
2017 ◽  
Vol 390 (10094) ◽  
pp. 555-566 ◽  
Author(s):  
H Miles Prince ◽  
Youn H Kim ◽  
Steven M Horwitz ◽  
Reinhard Dummer ◽  
Julia Scarisbrick ◽  
...  
Keyword(s):  
T Cell ◽  
Multicentre Trial ◽  
Cell Lymphoma ◽  
Brentuximab Vedotin ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Open Label ◽  
Phase 3

scholarly journals Our first experiences with brentuximab vedotin in the treatment of cutaneous T-cell lymphoma

2019 ◽  
Vol 95 (3) ◽  
pp. 129-135
Author(s):  
József Szakonyi ◽  
◽  
Veronika Tóth ◽  
Béla Tóth ◽  
Ágota Szepesi ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Brentuximab Vedotin ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma
Sign in / Sign up

Export Citation Format

Share Document